Building mRNA Vaccine Capacity in LMICs

Time: 3:30 pm
day: Day Two


  • Pandemic has highlighted inequity in terms of access between regions with vaccine manufacturing capacities and region with none. Following COVID-19 massive demands from LMICs for access to mRNA technology know-how and manufacturing capacity has raised
  • Multiple initiatives are underway to transfer mRNA technology to LMICs challenging with sustainability of infrastructures and know-how in absence of routine market. Minimize the risks of “build and bust” by careful evaluation of costs (CAPEX and OPEX) is essential
  • Development of mRNA vaccines against disease of LMICs importance (e.g. TB, HIV, malaria) can contribute to capacity sustainability and pandemic preparedness